dacetuzumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 460112574

| image =

| type = mab

| mab_type = mab

| source = zu/o

| target = CD40

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 880486-59-9

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = UT59FF4T5X

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| synonyms = SGN-40

| C=6452 | H=9964 | N=1732 | O=1998 | S=42

}}

Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody[http://www.ama-assn.org/ama1/pub/upload/mm/365/dacetuzumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab], American Medical Association. being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma{{cite journal | vauthors = Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG | display-authors = 6 | title = Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma | journal = Journal of Clinical Oncology | volume = 27 | issue = 26 | pages = 4371–7 | date = September 2009 | pmid = 19636010 | doi = 10.1200/JCO.2008.21.3017 | doi-access = free }} and hematological malignancies.{{cite journal | vauthors = Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ | title = Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies | journal = Current Opinion in Investigational Drugs | volume = 10 | issue = 6 | pages = 579–87 | date = June 2009 | pmid = 19513947 }}

This drug was developed by Seattle Genetics, Inc.